Sucampo Pharmaceuticals 10-Q 5 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 02, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Sucampo Pharmaceuticals, Inc.
Trading Symbol	scmp
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		45,244,412
Amendment Flag	false
Entity Central Index Key	1,365,216
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 71,343	$ 71,622
Investments, current	37,153	22,393
Product royalties receivable	16,136	18,576
Accounts receivable, net	8,202	5,338
Deferred tax assets, current	259	476
Deferred charge, current	295	295
Restricted cash, current	213	213
Inventory	308
Prepaid expenses and other current assets	2,804	3,411
Total current assets	136,713	122,324
Investments, non-current	16,655	13,540
Property and equipment, net	526	763
Intangible assets, net	141	151
Deferred tax assets, non-current	2,065	571
Deferred charge, non-current	1,548	1,695
Restricted cash, non-current	2,356	2,224
Other assets	253	306
Total assets	160,257	141,574
Current liabilities:
Accounts payable	3,910	4,143
Accrued expenses	8,660	8,467
Deferred revenue, current	1,728	2,051
Collaboration obligation	5,774	6,000
Income tax payable	2,279	1,291
Notes payable, current	8,411	8,240
Other current liabilities	2,079	3,618
Total current liabilities	32,841	33,810
Notes payable, non-current	13,330	17,578
Deferred revenue, non-current	4,801	5,118
Deferred tax liability, non-current	436	820
Other liabilities	2,125	1,936
Total liabilities	53,533	59,262
Stockholders' equity:
Preferred stock, $0.01 par value; 5,000,000 shares authorized at June 30, 2015 and December 31, 2014; no shares issued and outstanding at June 30, 2015 and December 31, 2014	0	0
Additional paid-in capital	92,238	83,646
Accumulated other comprehensive income	14,096	14,265
Treasury stock, at cost; 524,792 shares at June 30, 2015 and December 31, 2014	(2,313)	(2,313)
Retained earnings (accumulated deficit)	2,252	(13,732)
Total stockholders' equity	106,724	82,312
Total liabilities and stockholders' equity	160,257	141,574
Common Class A [Member]
Stockholders' equity:
Common stock value	451	446
Common Class B [Member]
Stockholders' equity:
Common stock value	$ 0	$ 0

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock,shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Treasury stock, shares	524,792	524,792
Common Class A [Member]
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	270,000,000	270,000,000
Common stock, shares issued	45,179,884	44,602,988
Common stock, shares outstanding	45,179,884	44,602,988
Common Class B [Member]
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) - Scenario, Unspecified [Domain] - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues:
Research and development revenue	$ 2,409	$ 1,700	$ 4,754	$ 3,484
Product royalty revenue	16,136	13,888	31,881	27,389
Product sales revenue	14,511	7,543	25,656	13,855
Co-promotion revenue		723		1,085
Contract and collaboration revenue	1,828	215	2,073	417
Total revenues	34,884	24,069	64,364	46,230
Costs and expenses:
Costs of goods sold	7,260	3,796	13,370	7,189
Research and development expenses	7,124	4,252	13,917	9,387
General and administrative expenses	8,328	8,197	14,611	15,454
Selling and marketing expenses	592	4,013	1,232	7,660
Total costs and expenses	23,304	20,258	43,130	39,690
Income from operations	11,580	3,811	21,234	6,540
Non-operating income (expense):
Interest income	53	23	93	80
Interest expense	(265)	(392)	(541)	(792)
Other income (expense), net	2,063	(53)	1,860	(376)
Total non-operating income (expense)	1,851	(422)	1,412	(1,088)
Income before income taxes	13,431	3,389	22,646	5,452
Income tax provision	(3,855)	(1,779)	(6,662)	(3,086)
Net income	$ 9,576	$ 1,610	$ 15,984	$ 2,366
Net income per share:
Basic (in Dollars per share)	$ 0.21	$ 0.04	$ 0.36	$ 0.05
Diluted (in Dollars per share)	$ 0.21	$ 0.04	$ 0.35	$ 0.05
Weighted average common shares outstanding:
Basic (in Shares)	44,627	43,640	44,497	43,521
Diluted (in Shares)	46,199	43,640	46,046	43,609
Comprehensive income:
Net income	$ 9,576	$ 1,610	$ 15,984	$ 2,366
Other comprehensive income (expense):
Unrealized loss on pension benefit obligation	(12)		(19)
Unrealized gain (loss) on investments, net of tax effect	18	(3)	12	5
Foreign currency translation loss	(337)	(126)	(162)	(245)
Comprehensive income	$ 9,245	$ 1,481	$ 15,815	$ 2,126

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders’ Equity (Unaudited) - 6 months ended Jun. 30, 2015 - USD ($) $ in Thousands	Common Class A [Member]Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2014	$ 446	$ 83,646	$ 14,265	$ (2,313)	$ (13,732)	$ 82,312
Balance (in Shares) at Dec. 31, 2014	44,602,988			524,792
Employee stock option expense		3,889				3,889
Stock issued under exercise of stock options	$ 5	3,729				3,734
Stock issued under exercise of stock options (in Shares)	573,956
Stock issued under employee stock purchase plan		38				38
Stock issued under employee stock purchase plan (in Shares)	2,940
Windfall tax benefit from stock-based compensation		936				936
Unrealized loss on pension benefit obligation			(19)			(19)
Unrealized loss on investments, net of tax effect			12			12
Foreign currency translation			(162)			(162)
Net income					15,984	15,984
Balance at Jun. 30, 2015	$ 451	$ 92,238	$ 14,096	$ (2,313)	$ 2,252	$ 106,724
Balance (in Shares) at Jun. 30, 2015	45,179,884			524,792

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net income	$ 15,984	$ 2,366
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	215	721
Loss on disposal of property and equipment	76
Deferred tax provision	(1,662)	(792)
Deferred charge	147	336
Stock-based compensation	3,889	832
Amortization of premiums on investments	76	50
Unrealized currency translations	(214)	$ 320
Shortfall from stock-based compensation	(69)
Transfer and assignment of licensing rights	(2,000)
Changes in operating assets and liabilities:
Accounts receivable	(2,755)	$ 652
Unbilled accounts receivable	(111)	(2)
Product royalties receivable	2,440	941
Inventory	(308)	(211)
Prepaid and income taxes receivable and payable, net	988	(1,209)
Accounts payable	(221)	(2,006)
Accrued expenses	255	548
Deferred revenue	(641)	(1)
Collaboration obligation	(226)
Accrued interest payable	(16)	(21)
Other assets and liabilities, net	(763)	1,571
Net cash provided by operating activities	15,084	4,095
Cash flows from investing activities:
Purchases of investments	(39,775)	(4,515)
Proceeds from the sales of investments	2,398	1,700
Maturities of investments	19,421	4,500
Purchases of property and equipment	(47)	(49)
Transfer and assignment of licensing rights	2,000
Net cash provided by (used in) investing activities	(16,003)	1,636
Cash flows from financing activities:
Repayment of notes payable	(4,077)	(3,906)
Proceeds from exercise of stock options	3,734	2,025
Proceeds from employee stock purchase plan	38	13
Proceeds from "at-the-market" stock issuance		5,327
Windfall benefit from stock-based compensation	1,005	81
Net cash provided by financing activities	700	3,540
Effect of exchange rates on cash and cash equivalents	(60)	159
Net increase (decrease) in cash and cash equivalents	(279)	9,430
Cash and cash equivalents at beginning of period	71,622	44,102
Cash and cash equivalents at end of period	$ 71,343	$ 53,532

Note 1 - Business Organization

Note 1 - Business Organization and Basis of Presentation	6 Months Ended
	Jun. 30, 2015
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Description of the Business Sucampo Pharmaceuticals, Inc. (the Company) is a global biopharmaceutical company focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. The Company is currently focused on developing compounds known as prostones, which are ion channel activators, to treat gastrointestinal and oncology-based inflammatory disorders. The Company currently generates revenue primarily from product royalties, development milestone payments, product sales and reimbursements for clinical development activities. The Company expects to continue to incur significant expenses for the next several years as the Company continues its research and development activities, seeks regulatory approvals and additional indications for approved products and other compounds and seeks strategic opportunities for in-licensing non-prostone clinical candidates. In the United States (U.S.), AMITIZA ® In Japan, AMITIZA is marketed under a license, commercialization and supply agreement (the Japan Mylan Agreement) that was transferred to Mylan, Inc. (Mylan) from Abbott Laboratories, Inc. (Abbott), as of February 27, 2015, as part of Mylan’s acquisition of a product portfolio from Abbott. Mylan markets AMITIZA in Japan for chronic constipation (CC) excluding constipation caused by organic diseases. AMITIZA is Japan’s only prescription medicine for CC. The Company did not experience any significant changes in the commercialization of AMITIZA in Japan as a result of the transfer of the Japan Mylan Agreement from Abbott to Mylan. In the People’s Republic of China, the Company entered into an exclusive license, development, commercialization and supply agreement (the China Gloria Agreement) with Harbin Gloria Pharmaceuticals Co., Ltd. (Gloria), for AMITIZA in May 2015. Gloria is responsible for all development activities and costs, as well as commercialization and regulatory activities, for AMITIZA in the People’s Republic of China. The Company will be the exclusive supplier of AMITIZA to Gloria at an agreed upon supply price and will be eligible for an additional milestone payment upon the occurrence of a regulatory or, alternatively, a commercial milestone event. As a result of this agreement, the Company recognized a payment of $1.0 million from Gloria, which is the first tranche of the $1.5 million upfront payment agreed to as part of the China Gloria Agreement. In June 2015, the China Food and Drug Administration (CFDA) accepted an Investigational New Drug (IND) application for a pivotal study of AMITIZA in patients with CIC. As a result of this acceptance, the Company recognized a payment of $500,000 from Gloria, which is the second tranche of the $1.5 million upfront payment. In October 2014, the Company entered into an exclusive license, development, commercialization and supply agreement (the Global Takeda License Agreement) for lubiprostone with Takeda, through which Takeda has the exclusive rights to further develop and commercialize AMITIZA in all global markets, except the U.S., Canada, Japan and the People’s Republic of China. In addition, Takeda will become the marketing authorization holder and will be responsible for all commercialization and regulatory activities in the areas covered by the Global License Agreement. In the United Kingdom (U.K.), the Company made AMITIZA available for CIC and in Switzerland, Takeda markets AMITIZA for CIC and OIC. The Company filed for the OIC indication in the U.K., but in March 2014 the Company received notification from the Medicines and Healthcare Products Regulatory Agency (MHRA) that the application for the OIC indication was not approved and the Company subsequently resubmitted the application for OIC for re-review to MHRA. The Company currently awaits MHRA’s decision on the OIC indication. In January 2015, the Company successfully completed the European mutual recognition procedure for AMITIZA for the treatment of CIC in select European countries, resulting in a recommendation for marketing authorization. As a result of that recommendation, Ireland, Belgium, the Netherlands, Luxembourg, Austria, Germany and Italy have approved AMITIZA for CIC, and the Company anticipates receiving approval by Spain in the second half of 2015. The Company’s clinical development programs include the following: Lubiprostone Alternate Formulation The Company is developing an alternate formulation of lubiprostone, both for adult and pediatric patients who are unable to take capsules and for naso-gastric tube fed patients. Takeda is funding 100% of the costs of this alternate formulation work and the Company expects to initiate a phase 3 trial of the alternate formulation of lubiprostone in adults in the second half of 2015. Lubiprostone for Pediatric Functional Constipation The phase 3 program required to support an application for marketing approval of lubiprostone for pediatric functional constipation comprises four clinical trials, two of which are currently ongoing and are both testing the soft gelatin capsule formulation of lubiprostone in patients 6 to 17 years of age. The first of the two trials is a pivotal 12-week, randomized, placebo-controlled trial which was initiated in December 2013. The second trial is a follow-on, long-term safety extension study which was initiated in March 2014. The Company is also evaluating the timing of the initiation of the additional two trials in its phase 3 program for pediatric functional constipation, which will be in children aged 6 months to less than 6 years and will require the alternate formulation of lubiprostone as described above. Cobiprostone for Oral Mucositis (OM) In the first quarter of 2014, the Company completed its phase 1b trial that evaluated the safety and pharmacokinetics of an orally applied liquid formulation of cobiprostone. In this phase 1b trial, cobiprostone was well-tolerated overall and revealed low systemic exposure. In May 2015, the FDA granted Fast Track Designation for cobiprostone for the prevention of OM. The FDA has also accepted the Company’s IND application to initiate a phase 2 clinical trial of cobiprostone for the prevention of OM in patients suffering with head and neck cancer receiving concurrent radiation and chemotherapy. The Company plans to initiate a phase 2a study in the second half of 2015. The Company had also filed for orphan drug designation in the European Union (E.U.) but in April 2015 withdrew the application as the target population was estimated to be too large for orphan drug status. Cobiprostone for Non-Erosive Reflux Disease (NERD)/Gastroesophageal Reflux Disease (GERD) In December of 2014, the Company initiated a phase 2a program for cobiprostone in NERD/GERD in patients who have had a non-satisfactory response to proton pump inhibitors. The study, conducted in Japan, is currently ongoing. Unoprostone Isopropyl In March 2015, the Company announced that it would return all licenses for unoprostone isopropyl to R-Tech Ueno, Ltd (R-Tech). These licenses had provided the Company with exclusive development and commercialization rights to unoprostone isopropyl globally except for Japan, the People’s Republic of China, Taiwan and Korea, and covered certain indications including the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, retinitis pigmentosa and geographic atrophy. Effective May 6, 2015, the Company and R-Tech executed a transfer and termination agreement to effectuate the return of the licenses as well as regulatory, commercial and pharmacovigilance information. As a result of this transfer and termination agreement, the Company received a payment of $2.6 million from R-Tech , consisting of $2.0 million for the transfer and assignment of certain rights and assets, and $0.6 million as a reimbursement of an FDA fee. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 9, 2015. The financial information as of June 30, 2015, the three and six months ended June 30, 2015, and the three and six months ended June 30, 2014 is unaudited. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG (SAG) based in Zug, Switzerland, through which the Company conducts certain of its worldwide and European operations; Sucampo Pharma, LLC (SPL) based in Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, (SPA) based in Bethesda, Maryland, through which the Company conducts its North American operations; and Sucampo Pharma Europe, Ltd., (SPE) based in Oxford, United Kingdom. All significant inter-company balances and transactions have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Certain Risks, Concentrations and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of June 30, 2015 and December 31, 2014, approximately $32.5 million, or 25.4%, and $37.0 million, or 33.6%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the U.S. government or U.S. government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits. Revenues from Takeda, an unrelated party, accounted for 53.6% and 68.1% of the Company’s total revenues for the three months ended June 30, 2015 and 2014, respectively, and 57.4% and 69.6% for the six months ended June 30, 2015 and 2014, respectively. Revenues from Mylan (formerly Abbott), an unrelated party, accounted for 41.6% and 30.0% of the Company’s total revenues for the three months ended June 30, 2015 and 2014, respectively, and 39.8% and 28.8% for the six months ended June 30, 2015 and 2014, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 73.7% and 88.5% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at June 30, 2015 and December 31, 2014, respectively. The Company depends significantly upon collaborations with Takeda and Mylan, and its revenues may be impacted if these relationships are disrupted. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued authoritative guidance which sets forth a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The guidance is effective for annual reporting periods, including interim reporting periods within those periods, beginning after December 15, 2016, and early adoption is not permitted. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is currently evaluating the impact of this guidance. On July 9, 2015, the FASB voted to defer the effective date of the above mentioned revenue recognition guidance by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016

Note 3 - Net Income per Share

Note 3 - Net Income per Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	3. Net Income per Share Basic net income per share is computed by dividing net income by the sum of the weighted average class A common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average common shares and potential dilutive common shares outstanding. Diluted net loss per share, when applicable, is computed by dividing net loss by the weighted average common shares outstanding without the impact of potential dilutive common shares outstanding because they would have an anti-dilutive impact on diluted net loss per share. The computation of net income per share for the three and six months ended June 30, 2015 and 2014 is shown below: Three Months Ended June 30, Six Months Ended June 30, (In thousands, except per share data) 2015 2014 2015 2014 Net income $ 9,576 $ 1,610 $ 15,984 $ 2,366 Basic net income per share: Weighted average class A common shares outstanding 44,627 43,640 44,497 43,521 Basic net income per share $ 0.21 $ 0.04 $ 0.36 $ 0.05 Diluted net income per share: Weighted average class A common shares outstanding 44,627 43,640 44,497 43,521 Assumed exercise of stock options under the treasury stock method 1,572 - 1,549 88 46,199 43,640 46,046 43,609 Diluted net income per share $ 0.21 $ 0.04 $ 0.35 $ 0.05 The following securities were excluded from the computation of diluted net income per share as their effect would be anti-dilutive for the three and six months ended June 30, 2015 and 2014: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2015 2014 2015 2014 Employee stock options 1,083 1,169 733 933

Note 4 - Current and Non-Curren

Note 4 - Current and Non-Current Investments	6 Months Ended
	Jun. 30, 2015
Investments Schedule [Abstract]
Investment [Text Block]	4. Current and Non-Current Investments At June 30, 2015 and December 31, 2014, current and non-current available-for-sale investments consisted of the following securities: June 30, 2015 (In thousands) Cost Unrealized Gains Unrealized Losses Fair Value Current: Certificates of deposit $ 7,000 $ - $ - $ 7,000 Commercial paper 8,489 10 - 8,499 Corporate bonds 13,735 - (9 ) 13,726 U.S. government agencies 7,428 - - 7,428 U.S. treasury bills and notes 500 - - 500 Total $ 37,152 $ 10 $ (9 ) $ 37,153 Non-current: Certificates of deposit $ 5,250 $ - $ - $ 5,250 U.S. government agencies 11,405 - - 11,405 Total $ 16,655 $ - $ - $ 16,655 December 31, 2014 (In thousands) Cost Unrealized Gains Unrealized Losses Fair Value Current: U.S. government securities $ 4,203 $ 1 $ - $ 4,204 Certificates of deposit 2,500 - - 2,500 Corporate bonds 4,575 - (3 ) 4,572 U.S. commercial paper 11,109 8 - 11,117 Total $ 22,387 $ 9 $ (3 ) $ 22,393 Non-current: U.S. government agencies $ 8,047 $ - $ (15 ) $ 8,032 Certificates of deposit 5,000 - - 5,000 Corporate bonds 509 - (1 ) 508 Total $ 13,556 $ - $ (16 ) $ 13,540 The Company performs fair value measurements in accordance with the Financial Accounting Standards Board’s guidance for fair value measurements and disclosures, which defines fair value as the exchange price that would be received for selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is established which requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company classifies its investments into the following categories based on the three levels of inputs used to measure fair value: Level 1 Level 2 Level 3 The Company’s assets measured at fair value on a recurring basis, including cash equivalents, which are subject to the fair value disclosure requirements, are as follows: Fair Value Measurements at Reporting Date Using June 30, 2015 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (In thousands) (Level 1) (Level 2) (Level 3) Total Certificates of deposit $ - $ 12,250 $ - $ 12,250 Commercial paper - 8,499 - 8,499 Corporate bonds - 13,727 - 13,727 Money market funds 6,185 - - 6,185 U.S. government agencies - 18,832 - 18,832 U.S. treasury bills and notes - 500 - 500 Total assets measured at fair value (a) $ 6,185 $ 53,808 $ - $ 59,993 (a) includes approximately $6.2 million of cash equivalents Fair Value Measurements at Reporting Date Using December 31, 2014 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (In thousands) (Level 1) (Level 2) (Level 3) Total U.S. government securities $ - $ 14,850 $ - $ 14,850 U.S. government agencies - 12,686 - 12,686 U.S. commercial paper - 15,092 - 15,092 Certificates of deposit - 8,000 - 8,000 Corporate bonds - 10,181 - 10,181 Money market funds 3,111 - - 3,111 Total assets measured at fair value (b) $ 3,111 $ 60,809 $ - $ 63,920 (b) includes approximately $28.0 million of cash equivalents If quoted prices in active markets for identical assets and liabilities are not available to determine fair value, then the Company uses quoted prices for similar assets and liabilities or inputs other than the quoted prices that are observable, either directly or indirectly. This pricing methodology applies to the Company’s Level 2 investments.

Note 5 - Inventory

Note 5 - Inventory	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	5. Inventory As of June 30, 2015, inventory consisted of product held under the Global Takeda License Agreement.

Note 6 - Accrued Expenses and O

Note 6 - Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Expenses and Other Current Liabilities Accrued expenses consist of the following as of June 30, 2015 and December 31, 2014: (In thousands) June 30, 2015 December 31, 2014 Research and development costs $ 1,932 $ 2,409 Commercial supplies 2,152 1,128 Employee compensation 2,130 3,459 Selling and marketing costs 11 163 Legal service fees 605 612 Other accrued expenses 1,830 696 Total $ 8,660 $ 8,467 Other current liabilities consisted of the following at June 30, 2015 and December 31, 2014: (In thousands) June 30, 2015 December 31, 2014 Indirect taxes payable $ 1,552 $ 3,075 Other liabilities 527 543 Total $ 2,079 $ 3,618 Indirect taxes payable was $1.6 million as of June 30, 2015 and $3.1 million as of December 31, 2014, a decrease of $1.5 million or 49.5%. The decrease in indirect taxes payable was due to the annual payment of an indirect tax.

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Operating Leases The Company leases office space in the United States, Switzerland and Japan under operating leases with terms through 2027. On May 5, 2015, the Company and Four Irvington Centre Associates, LLC entered into a Lease Agreement for the Company's new corporate headquarters located at 805 King Farm Boulevard in Rockville, Maryland (the Lease). The property subject to the Lease is a 24,244 square foot facility and the Company will be occupying the space for approximately $739,000 in annual rent, subject to annual increases over the term of the Lease, and excluding the Company's pro rata share of certain real property taxes, operating expenses, common area maintenance expenses and allowances for tenant improvements. The Lease has an initial term of 11 years and 7 months, commencing on December 1, 2015 (the Commencement Date). The Company has the option to extend the Lease for one period of five years, and may terminate the Lease beginning on the seventh anniversary of the Commencement Date, with the payment of certain termination costs. The Lease contains customary provisions allowing the landlord to terminate the Lease if the Company fails to remedy a breach of any of its obligations within specified time periods, or upon bankruptcy or insolvency of the Company. The Company has the ability to elect to expand the leased premises to include additional space at the new location by written election no later than January 1, 2020. Total future minimum, non-cancelable lease payments under operating leases, including the new Lease, are as follows: (In thousands) June 30, 2015 2015 $ 661 2016 1,187 2017 531 2018 786 2019 798 Total minimum lease payments $ 3,963 Rent expense for all operating leases was approximately $322,000 and $345,000 for the three months ended June 30, 2015 and 2014, respectively, and $655,000 and $696,000 for the six months ended June 30, 2015 and 2014, respectively. Research and Development Costs The Company routinely enters into agreements with third-party contract research organizations to oversee clinical research and development studies on an outsourced basis, and to assist in other research and development activities. The Company generally is not contractually obligated to pay the third party if the services or reports are not provided. Total future estimated costs under these agreements as of June 30, 2015 were approximately $7.1 million. Numab AG Commitment In September 2011, the Company entered into a Loan Guarantee and Development Agreement (Numab Agreement) with Numab AG (Numab). In the event that Numab defaults under its loan with Zurcher Kantonalbank, the Company’s maximum contingent liability under the Numab Agreement is $2.4 million. As of June 30, 2015, the potential amount of payments in the event of Numab’s default was $2.1 million. At June 30, 2015 the Company had a recorded liability of $1.0 million in collateral callable to meet a potential loan default by Numab.

Note 8 - Related Party Transact

Note 8 - Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	8. Related Party Transactions R-Tech Ueno, Ltd. The Company recorded the following expenses for the three and six months ended June 30, 2015 and 2014 under all of its agreements with R-Tech, including various exclusive supply agreements with R-Tech related to the supply of lubiprostone and cobiprostone: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2015 2014 2015 2014 Clinical supplies $ 6 $ 65 $ 37 $ 166 Other research and development services 84 21 89 31 Commercial supplies 7,036 4,080 13,178 7,626 $ 7,126 $ 4,166 $ 13,304 $ 7,823 The following table summarizes the amounts included in deferred revenue resulting from the deferral of upfront payments relating to the exclusive supply agreements with R-Tech as of June 30, 2015 and December 31, 2014: (In thousands) June 30, 2015 December 31, 2014 Deferred revenue, current $ 473 $ 453 Deferred revenue, non-current 3,907 4,141 $ 4,380 $ 4,594 The Company recognized approximately $335,000 and $104,000 of revenue relating to its agreements with R-Tech for the three months ended June 30, 2015 and 2014, respectively, and $473,000 and $268,000 for the six months ended June 30, 2015 and 2014, respectively. Such revenue was recorded as contract and collaboration revenue in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income. The Company recognized a $2.0 million payment from R-Tech for the transfer and assignment of certain rights and assets for the three and six months ended June 30, 2015. Such payment was recorded in other income (expense), net . The Company’s founders, Drs. Ryuji Ueno and Sachiko Kuno, individually or through S&R Technology Holdings, LLC, are no longer controlling stockholders of R-Tech as they completed an underwritten public offering in April 2015 to reduce their ownership in R-Tech to below 50.0%. Numab AG Numab is a related party of the Company as a result of the Company hiring as an executive officer an individual who holds an ownership interest in Numab. Under the terms of the Numab Agreement, the Company provided Numab with collateral and serves as guarantor for Numab on a loan from a third party, Zurcher Kantonalbank (see Note 7 above).

Note 9 - Notes Payable

Note 9 - Notes Payable	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	9. Notes Payable In connection with the Company’s acquisition of SAG in December 2010, the Company issued a subordinated unsecured promissory note to each of the Ueno Trust and the Kuno Trust (the Notes). The interest rate on the Notes beginning June 1, 2015 is 4.42%. Due to changes in LIBOR rates, the Company has estimated the fair value of the notes payable as shown in the table below. Notes payable at their fair value and carrying value consist of the following as of June 30, 2015 and December 31, 2014: Fair Value Carrying Value (In thousands) June 30, 2015 December 31, 2014 June 30, 2015 December 31, 2014 Promissory notes, Sellers of SAG $ 22,241 $ 26,317 $ 21,741 $ 25,818 Notes payable, current $ 8,411 $ 8,240 Notes payable, non-current 13,330 17,578 $ 21,741 $ 25,818 The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 above, and is classified as a Level 2 security.

Note 10 - Collaboration Obligat

Note 10 - Collaboration Obligation	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	10. Collaboration Obligation Under the Global Takeda License Agreement, the Company received an upfront payment from Takeda of $14.0 million in 2014, of which the Company is obligated to reimburse Takeda or fund the first $6.0 million in development expenses. The obligation as of June 30, 2015 totaled $5.8 million.

Note 11 - Collaboration and Lic

Note 11 - Collaboration and License Agreements	6 Months Ended
	Jun. 30, 2015
Collaborative And License Arrangement Disclosure [Abstract]
Collaborative And License Arrangement Disclosure [Text Block]	11. Collaboration and License Agreements North America Takeda Agreement The following table summarizes the cash streams and related revenue recognized or deferred under the North America Takeda Agreement for the six months ended June 30, 2015: (In thousands) Amount Deferred at December 31, 2014 Cash Received for the Six Months Ended June 30, 2015 Revenue Recognized for the Six Months Ended June 30, 2015 Change in Accounts Receivable for the Six Months Ended June 30, 2015* Amount Deferred at June 30, 2015 Collaboration revenue: Up-front payment associated with the Company's obligation to participate in joint committees $ 882 $ - $ 73 $ - $ 809 Research and development revenue: Reimbursement of research and development expenses $ - $ 4,055 $ 4,732 $ 1,616 $ - Product royalty revenue $ - $ 34,321 $ 31,881 $ (2,440 ) $ - * Includes billed and unbilled accounts receivable. Global Takeda License Agreement Product sales to Takeda under the Global Takeda License Agreement for the six months ended June 30, 2015 were approximately $8,000. Japan Mylan Agreement The following table summarizes the cash streams and related revenue recognized or deferred under the Japan Mylan Agreement for the six months ended June 30, 2015: (In thousands) Amount Deferred at December 31, 2014 Cash Received for the Six Months Ended June 30, 2015 Revenue Recognized for the Six Months Ended June 30, 2015 Change in Accounts Receivable for the Six Months Ended June 30, 2015 Foreign Currency Effects for the Six Months Ended June 30, 2015 Amount Deferred at June 30, 2015 Collaboration revenue: Up-front payment associated with the Company's obligation to participate in joint committees $ 453 $ - $ 17 $ - $ (13 ) $ 423 Product sales revenue $ - $ 22,930 $ 25,663 $ 2,283 $ 450 $ - China Gloria Agreement During the three months ended June 30, 2015, the Company recognized as Collaboration Revenue upfront payments of $1.5 million under the China Gloria Agreement.

Note 12 - Stock Option Plans

Note 12 - Stock Option Plans	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	12. Stock Option Plans A summary of the employee stock option activity for the six months ended June 30, 2015 under the Company’s Amended and Restated 2001 Stock Incentive Plan, or the 2001 Stock Incentive Plan, is presented below: Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Options outstanding, December 31, 2014 113,900 $ 10.00 Options exercised (76,500 ) 10.00 Options outstanding, June 30, 2015 37,400 10.00 0.84 $ 240,482 Options exercisable, June 30, 2015 37,400 10.00 0.84 $ 240,482 A summary of the non-employee stock option activity for the six months ended June 30, 2015 under the Company’s 2001 Stock Incentive Plan is presented below: Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Options outstanding, December 31, 2014 255,000 $ 5.85 Options exercised (127,500 ) 5.85 Options expired (127,500 ) 5.85 Options outstanding, June 30, 2015 - - - $ - Options exercisable, June 30, 2015 - - - $ - A summary of the employee stock option activity for the six months ended June 30, 2015 under the Company’s Amended and Restated 2006 Stock Incentive Plan is presented below: Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Options outstanding, December 31, 2014 4,021,491 $ 6.93 Options granted 1,174,100 14.88 Options exercised (369,956 ) 6.01 Options forfeited (67,038 ) 6.47 Options expired (3,924 ) 4.09 Options outstanding, June 30, 2015 4,754,673 8.97 8.34 $ 35,502,531 Options exercisable, June 30, 2015 1,606,732 6.36 6.00 $ 16,184,760 The weighted average grant date fair value of options granted during the six months ended June 30, 2015 and the year ended December 31, 2014 was $14.88 and $7.68, respectively. As of June 30, 2015, approximately $11.8 million of total unrecognized compensation costs, net of estimated forfeitures related to non-vested awards, are expected to be recognized over a weighted average period of 3.12 years. Employee Stock Purchase Plan Under the Company’s 2006 Employee Stock Purchase Plan, the Company received $26,607 and $7,839 upon the participants’ purchase of 1,990 and 1,196 shares of class A common stock during the three months ended June 30, 2015 and 2014, respectively, and $38,090 and $13,226 upon the participants’ purchase of 2,940 and 1,989 shares of class A common stock during the six months ended June 30, 2015 and 2014, respectively.

Note 13 - Pension Expense

Note 13 - Pension Expense	6 Months Ended
	Jun. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	13. Pension Expense Pension expenses relate to defined benefit pension plans for employees at SAG, the Company’s subsidiary in Switzerland (the Swiss Plan). The Swiss Plan is a government-mandated retirement fund that provides employees with a minimum investment return. The net periodic pension cost for the Swiss Plan included the following components for the six months ended June 30, 2015 and 2014: Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2015 2014 2015 2014 Service cost 47 48 94 96 Interest cost 7 11 14 22 Expected return on assets (10 ) (8 ) (20 ) (16 ) Amortization of unrecognized net loss 18 4 36 8 Net periodic pension cost 62 55 124 110

Note 14 - Income Taxes

Note 14 - Income Taxes	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	14. Income Taxes For the three months ended June 30, 2015 and 2014, the Company recorded tax provisions of $3.9 million and $1.8 million, respectively. For the six months ended June 30, 2015 and 2014, the Company recorded tax provisions of $6.7 million and $3.1 million, respectively. The tax provision for the three and six months ended June 30, 2015 primarily pertained to the mix of pre-tax profits generated by the Company’s U.S., Japanese and Swiss subsidiaries and pre-tax profits generated by the Company’s U.S. and Swiss subsidiaries for the three and six months ended June 30, 2014. The Company will continue to evaluate its valuation allowance position in each jurisdiction on a regular basis and may be in a position to reverse the valuation allowance on the deferred tax assets of its Swiss subsidiary in 2015. The potential tax benefit of such reversal would be approximately $150,000 if recognized in 2015. Uncertain Tax Positions The Company had an outstanding income tax liability of approximately $1.1 million, including interest, for uncertain tax positions as of June 30, 2015. The amount represented the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Condensed Consolidated Financial Statements. As of June 30, 2015, $263,000 is reflected as other current liabilities and $823,000 is reflected as other liabilities in the accompanying Condensed Consolidated Balance Sheets. The liability for uncertain tax positions as of June 30, 2015 mainly pertained to the Company’s interpretation of nexus in certain states related to revenue sourcing for state income tax purposes. During the three and six months ended June 30, 2015, the liability for income taxes has increased approximately $199,000 and increased approximately $244,000, respectively. These changes in the liability are primarily related to the filing positions taken in various jurisdictions related to income tax nexus.

Note 15 - Segment Reporting

Note 15 - Segment Reporting	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	15. Segment Reporting In the first quarter of 2015, the Company made a number of strategic and operational changes to its business, including re-evaluating and accelerating its pipeline to focus on clinical programs that it believes hold the most promise for patients, the highest likelihood for regulatory approval, and the strongest potential for commercial return. As a result of such changes, the Company combined its reportable geographic segments of Asia, the Americas and Europe into one operating segment: the development and commercialization of pharmaceutical products. This change reflects the manner in which information is now being presented internally and used by the Company’s chief operating decision maker, the Company’s Chief Executive Officer, to allocate resources and assess performance.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) and the rules and regulations of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 9, 2015. The financial information as of June 30, 2015, the three and six months ended June 30, 2015, and the three and six months ended June 30, 2014 is unaudited. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries: Sucampo AG (SAG) based in Zug, Switzerland, through which the Company conducts certain of its worldwide and European operations; Sucampo Pharma, LLC (SPL) based in Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, (SPA) based in Bethesda, Maryland, through which the Company conducts its North American operations; and Sucampo Pharma Europe, Ltd., (SPE) based in Oxford, United Kingdom. All significant inter-company balances and transactions have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Certain Risks, Concentrations and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of June 30, 2015 and December 31, 2014, approximately $32.5 million, or 25.4%, and $37.0 million, or 33.6%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the U.S. government or U.S. government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits. Revenues from Takeda, an unrelated party, accounted for 53.6% and 68.1% of the Company’s total revenues for the three months ended June 30, 2015 and 2014, respectively, and 57.4% and 69.6% for the six months ended June 30, 2015 and 2014, respectively. Revenues from Mylan (formerly Abbott), an unrelated party, accounted for 41.6% and 30.0% of the Company’s total revenues for the three months ended June 30, 2015 and 2014, respectively, and 39.8% and 28.8% for the six months ended June 30, 2015 and 2014, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 73.7% and 88.5% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at June 30, 2015 and December 31, 2014, respectively. The Company depends significantly upon collaborations with Takeda and Mylan, and its revenues may be impacted if these relationships are disrupted.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued authoritative guidance which sets forth a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The guidance is effective for annual reporting periods, including interim reporting periods within those periods, beginning after December 15, 2016, and early adoption is not permitted. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is currently evaluating the impact of this guidance. On July 9, 2015, the FASB voted to defer the effective date of the above mentioned revenue recognition guidance by one year to December 15, 2017 for interim and annual reporting periods beginning after that date and permitted early adoption of the standard, but not before the original effective date of December 15, 2016

Note 3 - Net Income per Share (

Note 3 - Net Income per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, (In thousands, except per share data) 2015 2014 2015 2014 Net income $ 9,576 $ 1,610 $ 15,984 $ 2,366 Basic net income per share: Weighted average class A common shares outstanding 44,627 43,640 44,497 43,521 Basic net income per share $ 0.21 $ 0.04 $ 0.36 $ 0.05 Diluted net income per share: Weighted average class A common shares outstanding 44,627 43,640 44,497 43,521 Assumed exercise of stock options under the treasury stock method 1,572 - 1,549 88 46,199 43,640 46,046 43,609 Diluted net income per share $ 0.21 $ 0.04 $ 0.35 $ 0.05
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2015 2014 2015 2014 Employee stock options 1,083 1,169 733 933

Note 4 - Current and Non-Curr24

Note 4 - Current and Non-Current Investments (Tables)	6 Months Ended
	Jun. 30, 2015
Investments Schedule [Abstract]
Available-for-sale Securities [Table Text Block]	June 30, 2015 (In thousands) Cost Unrealized Gains Unrealized Losses Fair Value Current: Certificates of deposit $ 7,000 $ - $ - $ 7,000 Commercial paper 8,489 10 - 8,499 Corporate bonds 13,735 - (9 ) 13,726 U.S. government agencies 7,428 - - 7,428 U.S. treasury bills and notes 500 - - 500 Total $ 37,152 $ 10 $ (9 ) $ 37,153 Non-current: Certificates of deposit $ 5,250 $ - $ - $ 5,250 U.S. government agencies 11,405 - - 11,405 Total $ 16,655 $ - $ - $ 16,655 December 31, 2014 (In thousands) Cost Unrealized Gains Unrealized Losses Fair Value Current: U.S. government securities $ 4,203 $ 1 $ - $ 4,204 Certificates of deposit 2,500 - - 2,500 Corporate bonds 4,575 - (3 ) 4,572 U.S. commercial paper 11,109 8 - 11,117 Total $ 22,387 $ 9 $ (3 ) $ 22,393 Non-current: U.S. government agencies $ 8,047 $ - $ (15 ) $ 8,032 Certificates of deposit 5,000 - - 5,000 Corporate bonds 509 - (1 ) 508 Total $ 13,556 $ - $ (16 ) $ 13,540
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements at Reporting Date Using June 30, 2015 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (In thousands) (Level 1) (Level 2) (Level 3) Total Certificates of deposit $ - $ 12,250 $ - $ 12,250 Commercial paper - 8,499 - 8,499 Corporate bonds - 13,727 - 13,727 Money market funds 6,185 - - 6,185 U.S. government agencies - 18,832 - 18,832 U.S. treasury bills and notes - 500 - 500 Total assets measured at fair value (a) $ 6,185 $ 53,808 $ - $ 59,993 Fair Value Measurements at Reporting Date Using December 31, 2014 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (In thousands) (Level 1) (Level 2) (Level 3) Total U.S. government securities $ - $ 14,850 $ - $ 14,850 U.S. government agencies - 12,686 - 12,686 U.S. commercial paper - 15,092 - 15,092 Certificates of deposit - 8,000 - 8,000 Corporate bonds - 10,181 - 10,181 Money market funds 3,111 - - 3,111 Total assets measured at fair value (b) $ 3,111 $ 60,809 $ - $ 63,920

Note 6 - Accrued Expenses and25

Note 6 - Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	(In thousands) June 30, 2015 December 31, 2014 Research and development costs $ 1,932 $ 2,409 Commercial supplies 2,152 1,128 Employee compensation 2,130 3,459 Selling and marketing costs 11 163 Legal service fees 605 612 Other accrued expenses 1,830 696 Total $ 8,660 $ 8,467
Other Current Liabilities [Table Text Block]	(In thousands) June 30, 2015 December 31, 2014 Indirect taxes payable $ 1,552 $ 3,075 Other liabilities 527 543 Total $ 2,079 $ 3,618

Note 7 - Commitments and Cont26

Note 7 - Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	(In thousands) June 30, 2015 2015 $ 661 2016 1,187 2017 531 2018 786 2019 798 Total minimum lease payments $ 3,963

Note 8 - Related Party Transa27

Note 8 - Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2015
Note 8 - Related Party Transactions (Tables) [Line Items]
Schedule of Related Party Transactions [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2015 2014 2015 2014 Clinical supplies $ 6 $ 65 $ 37 $ 166 Other research and development services 84 21 89 31 Commercial supplies 7,036 4,080 13,178 7,626 $ 7,126 $ 4,166 $ 13,304 $ 7,823
Agreements With R-Tech [Member]
Note 8 - Related Party Transactions (Tables) [Line Items]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	(In thousands) June 30, 2015 December 31, 2014 Deferred revenue, current $ 473 $ 453 Deferred revenue, non-current 3,907 4,141 $ 4,380 $ 4,594

Note 9 - Notes Payable (Tables)

Note 9 - Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Fair Value Carrying Value (In thousands) June 30, 2015 December 31, 2014 June 30, 2015 December 31, 2014 Promissory notes, Sellers of SAG $ 22,241 $ 26,317 $ 21,741 $ 25,818 Notes payable, current $ 8,411 $ 8,240 Notes payable, non-current 13,330 17,578 $ 21,741 $ 25,818

Note 11 - Collaboration and L29

Note 11 - Collaboration and License Agreements (Tables)	6 Months Ended
	Jun. 30, 2015
Takeda [Member]
Note 11 - Collaboration and License Agreements (Tables) [Line Items]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	(In thousands) Amount Deferred at December 31, 2014 Cash Received for the Six Months Ended June 30, 2015 Revenue Recognized for the Six Months Ended June 30, 2015 Change in Accounts Receivable for the Six Months Ended June 30, 2015* Amount Deferred at June 30, 2015 Collaboration revenue: Up-front payment associated with the Company's obligation to participate in joint committees $ 882 $ - $ 73 $ - $ 809 Research and development revenue: Reimbursement of research and development expenses $ - $ 4,055 $ 4,732 $ 1,616 $ - Product royalty revenue $ - $ 34,321 $ 31,881 $ (2,440 ) $ -
Abbott [Member]
Note 11 - Collaboration and License Agreements (Tables) [Line Items]
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	(In thousands) Amount Deferred at December 31, 2014 Cash Received for the Six Months Ended June 30, 2015 Revenue Recognized for the Six Months Ended June 30, 2015 Change in Accounts Receivable for the Six Months Ended June 30, 2015 Foreign Currency Effects for the Six Months Ended June 30, 2015 Amount Deferred at June 30, 2015 Collaboration revenue: Up-front payment associated with the Company's obligation to participate in joint committees $ 453 $ - $ 17 $ - $ (13 ) $ 423 Product sales revenue $ - $ 22,930 $ 25,663 $ 2,283 $ 450 $ -

Note 12 - Stock Option Plans (T

Note 12 - Stock Option Plans (Tables)	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Options outstanding, December 31, 2014 113,900 $ 10.00 Options exercised (76,500 ) 10.00 Options outstanding, June 30, 2015 37,400 10.00 0.84 $ 240,482 Options exercisable, June 30, 2015 37,400 10.00 0.84 $ 240,482 Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Options outstanding, December 31, 2014 255,000 $ 5.85 Options exercised (127,500 ) 5.85 Options expired (127,500 ) 5.85 Options outstanding, June 30, 2015 - - - $ - Options exercisable, June 30, 2015 - - - $ - Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Options outstanding, December 31, 2014 4,021,491 $ 6.93 Options granted 1,174,100 14.88 Options exercised (369,956 ) 6.01 Options forfeited (67,038 ) 6.47 Options expired (3,924 ) 4.09 Options outstanding, June 30, 2015 4,754,673 8.97 8.34 $ 35,502,531 Options exercisable, June 30, 2015 1,606,732 6.36 6.00 $ 16,184,760

Note 13 - Pension Expense (Tabl

Note 13 - Pension Expense (Tables)	6 Months Ended
	Jun. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Schedule of Net Benefit Costs [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, (In thousands) 2015 2014 2015 2014 Service cost 47 48 94 96 Interest cost 7 11 14 22 Expected return on assets (10 ) (8 ) (20 ) (16 ) Amortization of unrecognized net loss 18 4 36 8 Net periodic pension cost 62 55 124 110

Note 1 - Business Organizatio32

Note 1 - Business Organization and Basis of Presentation (Details) - USD ($)	May. 06, 2015	Jun. 30, 2015	May. 30, 2015	Jun. 30, 2015	Jun. 30, 2015
Note 1 - Business Organization and Basis of Presentation (Details) [Line Items]
Proceeds from Transfer and Assignment of Licensing Rights.					$ 2,000,000
Takeda [Member]
Note 1 - Business Organization and Basis of Presentation (Details) [Line Items]
Additional Reformulation Costs Funded, Percentage					100.00%
China Gloria Agreement [Member] | Gloria [Member]
Note 1 - Business Organization and Basis of Presentation (Details) [Line Items]
Collaboration Revenue from Upfront Payment				$ 1,500,000
China Gloria Agreement [Member] | First Tranche [Member] | Gloria [Member]
Note 1 - Business Organization and Basis of Presentation (Details) [Line Items]
Collaboration Revenue from Upfront Payment			$ 1,000,000
China Gloria Agreement [Member] | Second Tranche [Member] | Gloria [Member]
Note 1 - Business Organization and Basis of Presentation (Details) [Line Items]
Collaboration Revenue from Upfront Payment		$ 500,000
R-Tech [Member]
Note 1 - Business Organization and Basis of Presentation (Details) [Line Items]
Proceeds from Transfer and Termination Agreement	$ 2,600,000
Proceeds from Transfer and Assignment of Licensing Rights.	2,000,000
Proceeds from Reimbursement of FDA Fee	$ 600,000

Note 2 - Summary of Significa33

Note 2 - Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Cash, FDIC Insured Amount (in Dollars)	$ 32.5		$ 32.5		$ 37
Percentage of Deposit Within Federally Insured Limits	25.40%		25.40%		33.60%
Takeda [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	53.60%	68.10%	57.40%	69.60%
Takeda [Member] | Accounts Receivable, Unbilled Accounts Receivable and Product Royalties Receivable [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage			73.70%		88.50%
Mylan [Member] | Sales Revenue, Goods, Net [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	41.60%	30.00%	39.80%	28.80%

Note 3 - Net Income per Share34

Note 3 - Net Income per Share (Details) - Net Income (Loss) per Share - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Net Income (Loss) per Share [Abstract]
Net income (in Dollars)	$ 9,576	$ 1,610	$ 15,984	$ 2,366
Basic net income per share:
Weighted average class A common shares outstanding	44,627	43,640	44,497	43,521
Assumed exercise of stock options under the treasury stock method	1,572		1,549	88
	46,199	43,640	46,046	43,609
Diluted net income per share (in Dollars per share)	$ 0.21	$ 0.04	$ 0.35	$ 0.05
Basic net income per share (in Dollars per share)	$ 0.21	$ 0.04	$ 0.36	$ 0.05

Note 3 - Net Income per Share35

Note 3 - Net Income per Share (Details) - Antidilutive Securities - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Employee Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Employee stock options	1,083	1,169	733	933

Note 4 - Current and Non-Curr36

Note 4 - Current and Non-Current Investments (Details) - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Investments Schedule [Abstract]
Cash and Cash Equivalents, Fair Value Disclosure	$ 6.2	$ 28

Note 4 - Current and Non-Curr37

Note 4 - Current and Non-Current Investments (Details) - Summary of Current and Non-Current Investments - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current [Member]
Current:
Cost	$ 37,152	$ 22,387
Unrealized gains	10	9
Unrealized losses	(9)	(3)
Fair value	37,153	22,393
Current [Member] | Certificates of Deposit [Member]
Current:
Cost	7,000	2,500
Fair value	7,000	2,500
Current [Member] | Commercial Paper [Member]
Current:
Cost	8,489
Unrealized gains	10
Fair value	8,499
Current [Member] | Corporate Bond Securities [Member]
Current:
Cost	13,735	4,575
Unrealized losses	(9)	(3)
Fair value	13,726	4,572
Current [Member] | US Government Agencies Debt Securities [Member]
Current:
Cost	7,428	11,109
Unrealized gains		8
Fair value	7,428	11,117
Current [Member] | US Treasury Securities [Member]
Current:
Cost	500
Fair value	500
Current [Member] | US Treasury and Government [Member]
Current:
Cost		4,203
Unrealized gains		1
Fair value		4,204
Non-current [Member]
Current:
Cost	16,655	13,556
Unrealized losses		(16)
Fair value	16,655	13,540
Non-current [Member] | Certificates of Deposit [Member]
Current:
Cost	5,250	5,000
Fair value	5,250	5,000
Non-current [Member] | Corporate Bond Securities [Member]
Current:
Cost		509
Unrealized losses		(1)
Fair value		508
Non-current [Member] | US Government Agencies Debt Securities [Member]
Current:
Cost	11,405	8,047
Unrealized losses		(15)
Fair value	$ 11,405	$ 8,032

Note 4 - Current and Non-Curr38

Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis - USD ($) $ in Thousands	Jun. 30, 2015		Dec. 31, 2014
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	$ 59,993	[1]	$ 63,920	[2]
Certificates of Deposit [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	12,250		8,000
Commercial Paper [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	8,499		15,092
Corporate Bond Securities [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	13,727		10,181
Money Market Funds [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	6,185		3,111
US Government Agencies Debt Securities [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	18,832		12,686
US Treasury Securities [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	500
US Treasury and Government [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value			14,850
Fair Value, Inputs, Level 1 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	6,185	[1]	3,111	[2]
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	6,185		3,111
Fair Value, Inputs, Level 2 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	53,808	[1]	60,809	[2]
Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	12,250		8,000
Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	8,499		15,092
Fair Value, Inputs, Level 2 [Member] | Corporate Bond Securities [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	13,727		10,181
Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	18,832		12,686
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value	$ 500
Fair Value, Inputs, Level 2 [Member] | US Treasury and Government [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value			$ 14,850
Fair Value, Inputs, Level 3 [Member]
Note 4 - Current and Non-Current Investments (Details) - Assets Measured at Fair Value on Recurring Basis [Line Items]
Assets at fair value
[1]	includes approximately $6.2 million of cash equivalents
[2]	includes approximately $28.0 million of cash equivalents

Note 6 - Accrued Expenses and39

Note 6 - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Sales and Excise Tax Payable, Current	$ 1,552	$ 3,075
Increase (Decrease) in Property and Other Taxes Payable	$ (1,500)
Increase (Decrease) in Property and Other Taxes Payable, Percentage	(49.50%)

Note 6 - Accrued Expenses and40

Note 6 - Accrued Expenses and Other Current Liabilities (Details) - Summary of Accrued Expenses - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Summary of Accrued Expenses [Abstract]
Research and development costs	$ 1,932	$ 2,409
Commercial supplies	2,152	1,128
Employee compensation	2,130	3,459
Selling and marketing costs	11	163
Legal service fees	605	612
Other accrued expenses	1,830	696
Total	$ 8,660	$ 8,467

Note 6 - Accrued Expenses and41

Note 6 - Accrued Expenses and Other Current Liabilities (Details) - Other Current Liabilities Summary - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Other Current Liabilities Summary [Abstract]
Indirect taxes payable	$ 1,552	$ 3,075
Other liabilities	527	543
Total	$ 2,079	$ 3,618

Note 7 - Commitments and Cont42

Note 7 - Commitments and Contingencies (Details)	May. 05, 2015USD ($)ft²	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)
Note 7 - Commitments and Contingencies (Details) [Line Items]
Operating Leases, Rent Expense		$ 322,000	$ 345,000	$ 655,000	$ 696,000
Future Estimated Research and Development Costs				7,100,000
Guarantee of Indebtedness of Others [Member]
Note 7 - Commitments and Contingencies (Details) [Line Items]
Loss Contingency, Range of Possible Loss, Maximum		2,400,000		2,400,000
Loss Contingency, Estimate of Possible Loss		$ 2,100,000		2,100,000
Loss Contingency Accrual, Provision				$ 1,000,000
Four Irvington Centre [Member]
Note 7 - Commitments and Contingencies (Details) [Line Items]
Area of Real Estate Property (in Square Feet) | ft²	24,244
Operating Leases, Annual Rent Expense	$ 739,000
Lessee Leasing Arrangements, Operating Leases, Term of Contract	11 years 7 months
Lessee Leasing Arrangements, Operating Leases, Renewal Term	5 years

Note 7 - Commitments and Cont43

Note 7 - Commitments and Contingencies (Details) - Future Minimum, Non-Cancelable Lease Payments $ in Thousands	Jun. 30, 2015USD ($)
Future Minimum, Non-Cancelable Lease Payments [Abstract]
2,015	$ 661
2,016	1,187
2,017	531
2,018	786
2,019	798
Total minimum lease payments	$ 3,963

Note 8 - Related Party Transa44

Note 8 - Related Party Transactions (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Apr. 22, 2015
R-Tech [Member]
Note 8 - Related Party Transactions (Details) [Line Items]
Contracts Revenue	$ 335,000	$ 104,000	$ 473,000	$ 268,000
R-Tech [Member] | Transfer and Assignment of Rights and Assets [Member]
Note 8 - Related Party Transactions (Details) [Line Items]
Contracts Revenue	$ 2,000,000		$ 2,000,000
Drs. Ueno and Kuno [Member]
Note 8 - Related Party Transactions (Details) [Line Items]
Related Party, Ownership Percentage					50.00%

Note 8 - Related Party Transa45

Note 8 - Related Party Transactions (Details) - Expenses Under Agreements With R-Tech - R-Tech [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Related Party Transaction [Line Items]
Expenses related to R-Tech	$ 7,126	$ 4,166	$ 13,304	$ 7,823
Clinical Supplies [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	6	65	37	166
Other research and development services [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	84	21	89	31
Commercial supplies [Member]
Related Party Transaction [Line Items]
Expenses related to R-Tech	$ 7,036	$ 4,080	$ 13,178	$ 7,626

Note 8 - Related Party Transa46

Note 8 - Related Party Transactions (Details) - Deferred Revenues Under the Company’s Agreements With R-Tech - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Deferred Revenue Arrangement [Line Items]
Deferred revenue, current	$ 1,728	$ 2,051
Deferred revenue, non-current	4,801	5,118
R-Tech [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue, current	473	453
Deferred revenue, non-current	3,907	4,141
	$ 4,380	$ 4,594

Note 9 - Notes Payable (Details

Note 9 - Notes Payable (Details)	Jun. 01, 2015
Kuno and Ueno Trust [Member] | Subordinated Unsecured Promissory Notes [Member]
Note 9 - Notes Payable (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.42%

Note 9 - Notes Payable (Detai48

Note 9 - Notes Payable (Details) - Notes Payable - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Note 9 - Notes Payable (Details) - Notes Payable [Line Items]
Note Payable Carrying Value	$ 21,741	$ 25,818
Notes payable, current	8,411	8,240
Notes payable, non-current	13,330	17,578
SAG [Member]
Note 9 - Notes Payable (Details) - Notes Payable [Line Items]
Note Payable Fair Value	22,241	26,317
Note Payable Carrying Value	$ 21,741	$ 25,818

Note 10 - Collaboration Oblig49

Note 10 - Collaboration Obligation (Details) - Global License Agreement [Member] - Takeda [Member] - USD ($) $ in Millions	Jun. 30, 2015	Dec. 31, 2014
Note 10 - Collaboration Obligation (Details) [Line Items]
Development Expenses to be Assumed		$ 6
Developmental Expense Reimbursement Obligation	$ 5.8
Up-front Payment Arrangement [Member]
Note 10 - Collaboration Obligation (Details) [Line Items]
Deferred Revenue		$ 14

Note 11 - Collaboration and L50

Note 11 - Collaboration and License Agreements (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Note 11 - Collaboration and License Agreements (Details) [Line Items]
Sales Revenue, Goods, Net	$ 14,511,000	$ 7,543,000	$ 25,656,000	$ 13,855,000
China Gloria Agreement [Member] | Gloria [Member]
Note 11 - Collaboration and License Agreements (Details) [Line Items]
Collaboration Revenue from Upfront Payment	$ 1,500,000
Takeda [Member] | Global License Agreement [Member]
Note 11 - Collaboration and License Agreements (Details) [Line Items]
Sales Revenue, Goods, Net			$ 8,000

Note 11 - Collaboration and L51

Note 11 - Collaboration and License Agreements (Details) - Cash Streams and Related Revenue Recognized or Deferred Under the Takeda Agreement - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2015	Dec. 31, 2014
Reimbursement of Research and Development Expenses [Member]
Collaboration revenue:
Cash received		$ 4,055
Revenue recognized		4,732
Accounts receivable	[1]	1,616
Collaborative Arrangement [Member] | Takeda [Member]
Collaboration revenue:
Deferred revenue, balance		809	$ 882
Revenue recognized		$ 73
Accounts receivable	[1]
Product Royalty Revenue [Member] | Takeda [Member]
Collaboration revenue:
Cash received		$ 34,321
Revenue recognized		31,881
Accounts receivable	[1]	$ (2,440)
[1]	Includes billed and unbilled accounts receivable.

Note 11 - Collaboration and L52

Note 11 - Collaboration and License Agreements (Details) - Cash Streams and Related Revenue Recognized or Deferred Under the Japan Abbott Agreement - Abbott [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Collaborative Arrangement [Member]
Collaboration revenue:
Deferred revenue, balance	$ 423	$ 453
Revenue recognized	17
Foreign currency effects	(13)
Product Sales Revenue [Member]
Collaboration revenue:
Cash received	22,930
Revenue recognized	25,663
Accounts receivable	2,283
Foreign currency effects	$ 450

Note 12 - Stock Option Plans (D

Note 12 - Stock Option Plans (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Note 12 - Stock Option Plans (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)			$ 14.88		$ 7.68
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 11,800,000		$ 11,800,000
Stock Issued During Period, Value, Employee Stock Purchase Plan			38,000
Common Class A [Member] | 2006 Employee Stock Purchase Plan [Member]
Note 12 - Stock Option Plans (Details) [Line Items]
Stock Issued During Period, Value, Employee Stock Purchase Plan	$ 26,607	$ 7,839	$ 38,090	$ 13,226
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)	1,990	1,196	2,940	1,989
Employee Stock Option [Member]
Note 12 - Stock Option Plans (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			3 years 43 days

Note 12 - Stock Option Plans 54

Note 12 - Stock Option Plans (Details) - Stock Option Activity - Jun. 30, 2015 - USD ($)	Total
2001 Incentive Plan [Member]
Note 12 - Stock Option Plans (Details) - Stock Option Activity [Line Items]
Options Outstanding	37,400
Options Outstanding, Weighted Average Exercise Price Per Share	$ 10
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	306 days
Options Outstanding, Aggregate Intrinsic Value	$ 240,482
Options exercisable	37,400
Options exercisable, Weighted Average Exercise Price Per Share	$ 10
Options exercisable, Weighted Average Remaining Contractual Term (Years)	306 days
Options exercisable, Aggregate Intrinsic Value	$ 240,482
Options exercised	(76,500)
Options exercised, Weighted Average Exercise Price Per Share	$ 10
Non Employee Stock Plan 2001 [Member]
Note 12 - Stock Option Plans (Details) - Stock Option Activity [Line Items]
Options exercised	(127,500)
Options exercised, Weighted Average Exercise Price Per Share	$ 5.85
Options expired	(127,500)
Options expired, Weighted Average Exercise Price Per Share	$ 5.85
Stock Incentive Plan 2006 [Member]
Note 12 - Stock Option Plans (Details) - Stock Option Activity [Line Items]
Options Outstanding	4,754,673
Options Outstanding, Weighted Average Exercise Price Per Share	$ 8.97
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	8 years 124 days
Options Outstanding, Aggregate Intrinsic Value	$ 35,502,531
Options granted	1,174,100
Options granted	$ 14.88
Options exercisable	1,606,732
Options exercisable, Weighted Average Exercise Price Per Share	$ 6.36
Options exercisable, Weighted Average Remaining Contractual Term (Years)	6 years
Options exercisable, Aggregate Intrinsic Value	$ 16,184,760
Options exercised	(369,956)
Options exercised, Weighted Average Exercise Price Per Share	$ 6.01
Options forfeited	(67,038)
Options forfeited	$ 6.47
Options expired	(3,924)
Options expired, Weighted Average Exercise Price Per Share	$ 4.09

Note 13 - Pension Expense (Deta

Note 13 - Pension Expense (Details) - Net Periodic Benefit Cost Recognized - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Net Periodic Benefit Cost Recognized [Abstract]
Service cost	$ 47	$ 48	$ 94	$ 96
Interest cost	7	11	14	22
Expected return on assets	(10)	(8)	(20)	(16)
Amortization of unrecognized net loss	18	4	36	8
Net periodic pension cost	$ 62	$ 55	$ 124	$ 110

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2015
Note 14 - Income Taxes (Details) [Line Items]
Income Tax Expense (Benefit)	$ 3,855,000	$ 1,779,000	$ 6,662,000	$ 3,086,000
Liability For Uncertain Tax Positions	1,100,000		1,100,000
Increase (Decrease) in Income Taxes			988,000	$ (1,209,000)
Other Current Liabilities [Member]
Note 14 - Income Taxes (Details) [Line Items]
Liability for Uncertain Tax Positions, Current	263,000		263,000
Other Noncurrent Liabilities [Member]
Note 14 - Income Taxes (Details) [Line Items]
Liability for Uncertain Tax Positions, Noncurrent	823,000		823,000
Scenario, Forecast [Member]
Note 14 - Income Taxes (Details) [Line Items]
Income Tax Expense (Benefit)					$ (150,000)
State and Local Jurisdiction [Member]
Note 14 - Income Taxes (Details) [Line Items]
Increase (Decrease) in Income Taxes	$ 199,000		$ 244,000

Note 15 - Segment Reporting (De

Note 15 - Segment Reporting (Details)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Number of Operating Segments	1

Uncategorized Items - scmp-2015

Label	Element	Value
Non Employee Stock Plan 2001 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	$ 5.85
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	255,000
Stock Incentive Plan 2006 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	$ 6.93
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4,021,491
Two Thousand One Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	$ 10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	113,900